Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 828,958 shares, an increase of 57.1% from the May 14th total of 527,786 shares. Based on an average daily volume of 263,322 shares, the days-to-cover ratio is presently 3.1 days. Currently, 15.7% of the company’s stock are short sold.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Tuesday, April 21st. Wall Street Zen cut Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $22.00.

Hedge Funds Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC purchased a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent reporting period. 15.52% of the stock is currently owned by institutional investors.

Moleculin Biotech Stock Down 0.2%

Shares of Moleculin Biotech stock traded down $0.01 on Tuesday, reaching $2.71. The company’s stock had a trading volume of 118,284 shares, compared to its average volume of 181,175. The company has a market capitalization of $14.44 million, a price-to-earnings ratio of -0.15 and a beta of 1.77. The firm’s fifty day simple moving average is $2.47 and its two-hundred day simple moving average is $3.37. Moleculin Biotech has a 52 week low of $1.79 and a 52 week high of $24.00.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21). As a group, research analysts predict that Moleculin Biotech will post -5.1 EPS for the current year.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.